PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.73%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
1.31%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-2.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-70.59%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-69.48%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-69.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-3.03%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.09%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.93%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-34.43%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-46.04%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
57.48%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
125.75%
5Y revenue/share CAGR similar to AVGO's 122.61%. Walter Schloss might see both companies benefiting from the same mid-term trends.
69.50%
3Y revenue/share CAGR 1.25-1.5x AVGO's 60.90%. Bruce Berkowitz might see better product or regional expansions than the competitor.
176.00%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
39.23%
5Y OCF/share CAGR at 50-75% of AVGO's 73.80%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-6.21%
Negative 3Y OCF/share CAGR while AVGO stands at 34.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
581.29%
Net income/share CAGR at 75-90% of AVGO's 691.11%. Bill Ackman would press for strategic moves to boost long-term earnings.
765.91%
5Y net income/share CAGR 1.25-1.5x AVGO's 651.30%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
79.28%
3Y net income/share CAGR 1.25-1.5x AVGO's 66.58%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
194.56%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
15.59%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
20.14%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
40.48%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
37.98%
5Y dividend/share CAGR at 50-75% of AVGO's 71.80%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
41.93%
3Y dividend/share CAGR similar to AVGO's 38.29%. Walter Schloss finds parallel short-term dividend strategies for both companies.
8.29%
AR growth well above AVGO's 14.59%. Michael Burry fears inflated revenue or higher default risk in the near future.
11.69%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.18%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-3.02%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
6.34%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.35%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.